J Gynecol Oncol.  2021 Mar;32(2):e31. 10.3802/jgo.2021.32.e31.

A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)

• Lee YJ
• Lim MC
• Kim BG
• Ngoi NY
• Choi CH
• Park SY
• Tan DS
• Go Y
• Lee JY

• KMID: 2526377
• DOI: http://doi.org/10.3802/jgo.2021.32.e31

Abstract

Background
The optimal treatment of BRCA wild-type patients with platinum-sensitive recurrent ovarian cancer remains unknown. Recently, there is an increase in the evidence to support the role of the combination of a poly(adenosine diphosphate-ribose) polymerase inhibitor, anti-angiogenic agents, and immunotherapy as maintenance therapy in BRCA wild-type patients with platinum-sensitive recurrence. We hypothesized that adding pembrolizumab and bevacizumab to olaparib maintenance can increase progression-free survival (PFS) in BRCA wild-type patients with platinum-sensitive recurrent ovarian cancer.
Methods
BRCA wild-type patients who received two previous courses of platinum-containing therapy, achieved complete or partial response to last treatment, and the treatment-free interval is >6 months after the penultimate platinum-based chemotherapy offered olaparib maintenance with pembrolizumab and bevacizumab. Forty-four patients will be included from 4 sites across Singapore and Korea. The primary endpoint of the study is 6-month PFS rate.

Keyword

Ovarian Neoplasms; Bevacizumab; Poly(ADP-ribose) Polymerase Inhibitors; Immunotherapy Recurrence